Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combinations and biomarker prediction study in advanced hepatocellular carcinoma
ChiCTR2000040396Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab, Rivoceranib and sorafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: progression-free survival, disease control rate and 2 more. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000040396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040396.